(Alliance News) - OptiBiotix Health PLC on Wednesday said a human study of a food supplement formulation containing its LPLDL product shows it can reduce high blood pressure.
The study was conducted in partnership with Nutrilinea Srl, which has funded the development and manufacture of a new blood pressure product containing LPLDL, as well as human studies, in exchange for 12 months' exclusivity for the European market.
LPLDL is a naturally occurring strain of the probiotic bacteria Lactobacillus plantarum. OptiBiotix's ProBiotix Health Ltd unit retains exclusivity for the product in the UK and all other markets outside of Europe.
The three-month LPLDL study in 40 patients showed a statistically significant drop in systolic and diastolic blood pressure levels, as well as in cholesterol levels. This is consistent with an initial ProBiotix study of LPLDL published in 2017.
ProBiotix Chief Executive Steve Prescott said: "We are very pleased to have partnered with Nutrilinea who covered the cost of the product development, manufacturing, and the human study. Because hypertension effects millions of people globally and is a serious risk factor for cardiovascular disease, we are excited to offer a natural product that has been clinically proven to lower hypertension. Adding this new formulation to our portfolio of existing products that target cholesterol reduction, CholBiome and CholBiome x3, allows ProBiotix to offer a best in class cardiovascular health solutions to consumers."
Shares in York-headquartered OptiBiotix were up 0.9% at 57.00 pence in London on Wednesday morning.
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
OptiBiotix Health (OPTI)